Alnylam Pharmaceuticals' (ALNY) Outperform Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday morning, RTT News reports. A number of other equities analysts have also weighed in on ALNY. Citigroup decreased their target price on Alnylam Pharmaceuticals from $266.00 to $233.00 and set a […]

Related Keywords

Blackrock ,New Zealand General ,New Zealand ,Wellington ,William Blair ,Sanfordc Bernstein ,Michaelw Bonney ,Hedge Funds Weigh In On Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Company Profile ,Needham Company ,Analyst Recommendations For Alnylam Pharmaceuticals ,News Ratings For Alnylam Pharmaceuticals Daily ,Blackrock Inc ,Vanguard Group Inc ,Wellington Management Group ,T Rowe Price Investment Management Inc ,Alnylam Pharmaceuticals Stock Performance ,Alnylam Pharmaceuticals ,Citigroup ,Alnylam Pharmaceuticals Inc ,Free Report ,Moderate Buy ,Get Free Report ,Director Michael ,Management Group ,Rowe Price Investment Management ,State Street Corp ,Street Corp ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Reiterated Rating ,